These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 24692404)

  • 1. Embryofetal development study of vismodegib, a hedgehog pathway inhibitor, in rats.
    Morinello E; Pignatello M; Villabruna L; Goelzer P; Bürgin H
    Birth Defects Res B Dev Reprod Toxicol; 2014 Apr; 101(2):135-43. PubMed ID: 24692404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors.
    Lorusso PM; Jimeno A; Dy G; Adjei A; Berlin J; Leichman L; Low JA; Colburn D; Chang I; Cheeti S; Jin JY; Graham RA
    Clin Cancer Res; 2011 Sep; 17(17):5774-82. PubMed ID: 21753154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma.
    Cirrone F; Harris CS
    Clin Ther; 2012 Oct; 34(10):2039-50. PubMed ID: 23036338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
    Proctor AE; Thompson LA; O'Bryant CL
    Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of melamine on pregnant dams and embryo-fetal development in rats.
    Kim SH; Lee IC; Lim JH; Shin IS; Moon C; Kim SH; Park SC; Kim HC; Kim JC
    J Appl Toxicol; 2011 Aug; 31(6):506-14. PubMed ID: 21706515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vismodegib: a promising drug in the treatment of basal cell carcinomas.
    Dirix L; Rutten A
    Future Oncol; 2012 Aug; 8(8):915-28. PubMed ID: 22894666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
    Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
    J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of ponatinib with Hedgehog antagonist vismodegib for therapy-resistant BCR-ABL1-positive leukemia.
    Katagiri S; Tauchi T; Okabe S; Minami Y; Kimura S; Maekawa T; Naoe T; Ohyashiki K
    Clin Cancer Res; 2013 Mar; 19(6):1422-32. PubMed ID: 23319824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absorption, distribution, metabolism, and excretion of [¹⁴C]GDC-0449 (vismodegib), an orally active hedgehog pathway inhibitor, in rats and dogs: a unique metabolic pathway via pyridine ring opening.
    Yue Q; Chen YH; Mulder T; Deese A; Takahashi R; Rudewicz PJ; Reynolds M; Solon E; Hop CE; Wong H; Khojasteh SC
    Drug Metab Dispos; 2011 Jun; 39(6):952-65. PubMed ID: 21363998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dermal developmental toxicity of N-phenylimide herbicides in rats.
    Kawamura S; Kato T; Nakaoka M; Fantel AG
    Birth Defects Res B Dev Reprod Toxicol; 2014 Apr; 101(2):162-7. PubMed ID: 24753331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-response effects of diphenylhydantoin on pregnant dams and embryo-fetal development in rats.
    Kim SH; Lee IC; Baek HS; Lim JH; Moon C; Shin DH; Kim SH; Park SC; Kim JC
    Birth Defects Res B Dev Reprod Toxicol; 2012 Oct; 95(5):337-45. PubMed ID: 22887608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developmental toxicity and toxicokinetics of two endothelin receptor antagonists in rats and rabbits.
    Treinen KA; Louden C; Dennis MJ; Wier PJ
    Teratology; 1999 Jan; 59(1):51-9. PubMed ID: 9988883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry.
    Graham RA; Lum BL; Morrison G; Chang I; Jorga K; Dean B; Shin YG; Yue Q; Mulder T; Malhi V; Xie M; Low JA; Hop CE
    Drug Metab Dispos; 2011 Aug; 39(8):1460-7. PubMed ID: 21602311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NTP Toxicology and Carcinogenesis Studies of o-Benzyl-p-Chlorophenol (CAS No. 120-32-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1994 Jan; 424():1-304. PubMed ID: 12616287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification, characterization, and implications of species-dependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449).
    Giannetti AM; Wong H; Dijkgraaf GJ; Dueber EC; Ortwine DF; Bravo BJ; Gould SE; Plise EG; Lum BL; Malhi V; Graham RA
    J Med Chem; 2011 Apr; 54(8):2592-601. PubMed ID: 21438527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment.
    Abou-Alfa GK; Lewis LD; LoRusso P; Maitland M; Chandra P; Cheeti S; Colburn D; Williams S; Simmons B; Graham RA
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):29-36. PubMed ID: 28523596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms and efficacy of vismodegib in the treatment of basal cell carcinoma.
    Amin SH; Motamedi KK; Ochsner MC; Song TE; Hybarger CP
    Discov Med; 2013 Nov; 16(89):229-32. PubMed ID: 24229739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developmental toxicity of lersivirine in rabbits when administered throughout organogenesis and when limited to sensitive windows of axial skeletal development.
    Campion SN; Bowman CJ; Cappon GD; Harrison A; Finch GL; Hurtt ME
    Birth Defects Res B Dev Reprod Toxicol; 2012 Jun; 95(3):250-61. PubMed ID: 22495820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigations into the mechanisms of pyridine ring cleavage in vismodegib.
    Khojasteh SC; Yue Q; Ma S; Castanedo G; Chen JZ; Lyssikatos J; Mulder T; Takahashi R; Ly J; Messick K; Jia W; Liu L; Hop CE; Wong H
    Drug Metab Dispos; 2014 Mar; 42(3):343-51. PubMed ID: 24389420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The novel use of a heterozygous knockout mouse for embryofetal development assessment of a glucokinase activator.
    Mitchard T; Stewart J
    Birth Defects Res B Dev Reprod Toxicol; 2014 Apr; 101(2):152-61. PubMed ID: 24753370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.